Skip to main content
Log in

Kardiale Medikation bei COPD

Ein Betablocker bei Herzschwäche plus COPD ist gut — aber nicht jeder!

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Ni Y, Shi G, Wan H. Use of cardioselective beta-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res. 2012;40:2051–65.

    Article  CAS  PubMed  Google Scholar 

  2. Worth H. Beta-Blocker bei Asthma und COPD - ein therapeutisches Dilemma? Pneumologie 2001;55:53–6.

    Article  CAS  PubMed  Google Scholar 

  3. Packer M, Bristiw MB, Roecker EB et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–55.

    Article  CAS  PubMed  Google Scholar 

Literatur

  • Kubota Y, Asai K, Furuse E et al. Impact of Betablocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015;10:515–23.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Justus de Zeeuw.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Zeeuw, J. Ein Betablocker bei Herzschwäche plus COPD ist gut — aber nicht jeder!. Pneumo News 7, 15–16 (2015). https://doi.org/10.1007/s15033-015-0217-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-015-0217-5

Navigation